We are analyzing https://link.springer.com/chapter/10.1007/0-387-27545-2_10.

Title:
Cancer Vaccines in Combination with Multimodality Therapy | SpringerLink
Description:
Improvements in our understanding of tumor immunology have facilitated significant progress in the development of cancer vaccines. Early clinical trials have generated evidence for the safety of tumor vaccines, and have provided a suggestion of clinically significant...
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Education
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't tell how the site generates income.

The purpose of some websites isn't monetary gain; they're meant to inform, educate, or foster collaboration. Everyone has unique reasons for building websites. This could be an example. Link.springer.com has a revenue plan, but it's either invisible or we haven't found it.

Keywords {🔍}

google, scholar, cas, pubmed, cancer, article, tumor, cell, res, clin, vaccines, immunol, immune, cells, vaccine, melanoma, oncol, metastatic, mice, immunity, therapy, treatment, patients, monoclonal, antibody, chapter, clinical, chemotherapy, response, expression, antitumor, proc, sci, jaffee, immunotherapy, breast, acad, research, emens, reilly, autologous, cyclophosphamide, class, colonystimulating, factor, humoral, combination, development, drugs, responses,

Topics {✒️}

granulocyte-macrophage colony-stimulating factor intergroup trial e1694/s9512/c509801 long-lasting anti-tumor immunity class i-restricted her2-specific apo2/trail-mediated apoptosis bone marrow-derived cells antigen-experienced tumor-specific lymphocytes low-dose melphalan therapy gm2-klh/qs-21 vaccine month download article/chapter gm-csf secreting taxane-mediated gene induction protracted low-dose effects her2-overexpressing tumor cells indolent lympho-plasmacytic lymphoma graft-versus-tumor effect anti-tumor immune response anti-cd20 monoclonal antibody vivo gene transfer monoclonal antibody-mediated eradication allogeneic tumor vaccine potent humoral response peptide-based vaccination correlates mopc-315 tumor-bearing mice t-cell recognition 2/neu-expressing mammary tumor 5-aza-2′-deoxycytidine-induced expression prostate cancer antigens prostate cancer cells host antitumor immunity antigen-specific ctl response homeostasis-driven proliferation human solid tumors demonstrate antitumor activity dendritic cell administration autologous testicular cells privacy choices/manage cookies breast cell lines large mopc-315 tumor antitumor immune responses recurrent metastatic melanoma chemically induced tumors southwest oncology group melphalan-induced expression tumor-eradicating immunity device instant download neoadjuvant paclitaxel chemotherapy monoclonal antibodies trastuzumab cancer vaccine formulation chapter tumor immunology

Questions {❓}

Can the low-avidity self-specific T cell repertoire be expoited for tumor rejection?
Chemotherapy: friend or foe to cancer vaccines?
Humoral and cellular immune responses: independent forces or collaborators in the fight against cancer?

Schema {🗺️}

ScholarlyArticle:
      headline:Cancer Vaccines in Combination with Multimodality Therapy
      pageEnd:245
      pageStart:227
      image:https://media.springernature.com/w153/springer-static/cover/book/978-0-387-27545-1.jpg
      genre:
         Medicine
         Medicine (R0)
      isPartOf:
         name:Tumor Immunology and Cancer Vaccines
         isbn:
            978-0-387-27545-1
            978-1-4020-8119-4
         type:Book
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Leisha A. Emens
            affiliation:
                  name:The Johns Hopkins University, School of Medicine
                  address:
                     name:Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University, School of Medicine, Baltimore
                     type:PostalAddress
                  type:Organization
            type:Person
            name:R. Todd Reilly
            affiliation:
            type:Person
            name:Elizabeth M. Jaffee
            affiliation:
            type:Person
      keywords:Clin Oncol, Immune Tolerance, Cancer Vaccine, Antitumor Immunity, Multimodality Therapy
      description:Improvements in our understanding of tumor immunology have facilitated significant progress in the development of cancer vaccines. Early clinical trials have generated evidence for the safety of tumor vaccines, and have provided a suggestion of clinically significant bioactivity. They have also highlighted the challenges of cancer vaccine development. These include developing strategies for overcoming immune tolerance, and approaches for identifying the most active tumor rejection antigens for cancer vaccine formulation. Furthermore, these early studies highlight the importance of identifying important pharmacodynamic interactions between standard cancer treatment modalities and tumor vaccines. Surgical debulking is one approach for minimizing the impact of tumor burden, and patients with minimal residual disease are likely to be the most ideal candidates for vaccine therapy. The impact of chemotherapy on vaccine activity is a developing area of clinical research, with regard to both its positive and negative impact on the development of antigenspecific immunity. The impact of ionizing radiation on the immune response to cancer vaccines is an underdeveloped area that also warrants further investigation. Finally, the advent of biologically targeted therapies such as the monoclonal antibodies Trastuzumab and Rituximab offer new opportunities for combining cancer vaccines with novel drugs in combinatorial treatment strategies with the potential for significant synergism. It is clear that the careful preclinical and clinical investigation of these issues will guide the most effective clinical testing of cancer vaccines, and facilitate their ultimate incorporation into standard clinical practice.
      datePublished:2005
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
      context:https://schema.org
Book:
      name:Tumor Immunology and Cancer Vaccines
      isbn:
         978-0-387-27545-1
         978-1-4020-8119-4
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:The Johns Hopkins University, School of Medicine
      address:
         name:Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University, School of Medicine, Baltimore
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Leisha A. Emens
      affiliation:
            name:The Johns Hopkins University, School of Medicine
            address:
               name:Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University, School of Medicine, Baltimore
               type:PostalAddress
            type:Organization
      name:R. Todd Reilly
      affiliation:
      name:Elizabeth M. Jaffee
      affiliation:
PostalAddress:
      name:Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University, School of Medicine, Baltimore
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(253)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js

4.83s.

LINK . SPRINGER . COM {}